Association of Thrombus Aspiration With Time and Mortality Among Patients With ST-Segment Elevation Myocardial Infarction
Authors: Rachel Moxham, Vladimír Džavík, John Cairns, Madhu K. Natarajan, Kevin R. Bainey, Elie Akl, Michael B. Tsang, Shahar Lavi, Warren J. Cantor, Mina Madan, Yan Yun Liu, Sanjit S. Jolly
Journal: JAMA Network Open (2021)

<h3>Importance</h3> Patients with shorter ischemic times have a greater viable myocardium and may derive greater benefit from thrombus aspiration. <h3>Objective</h3> To study the association of thrombus aspiration with outcomes among patients presenting with ST-segment elevation myocardial infarction (STEMI) based on time. <h3>Design, Setting, and Participants</h3> The TOTAL (Thrombectomy With PCI vs PCI Alone in Patients with STEMI) trial was an international randomized clinical trial of 10 732 patients with STEMI undergoing primary percutaneous coronary intervention (PCI) within 12 hours of symptom onset. Patients were recruited between August 5, 2010, and July 25, 2014, and were followed up for 1 year. Data analysis was performed from February 22, 2019, to January 5, 2021. <h3>Interventions</h3> Thrombus aspiration vs PCI alone. <h3>Main Outcomes and Measures</h3> Post hoc subgroup analyses were performed for total ischemic time and first medical contact (FMC)–to–device time for the primary outcomes (cardiovascular [CV] mortality, myocardial Infarction [MI], cardiogenic shock, and New York Heart Association class IV heart failure) and angiographically determined distal embolization. In addition, a multivariable analysis was performed to assess the association of total ischemic time and FMC-to-device time with CV mortality at 1 year. <h3>Results</h3> The study randomized 10 732 patients, and 9986 underwent primary PCI and had time data available (7737 men [77.5%]; mean [SD] age, 61.0 [12.0] years). For the randomized comparison of thrombus aspiration, there was a reduction in angiographic distal embolization with thrombus aspiration that was more pronounced in patients with short ischemic times (&lt;2 hours: odds ratio [OR], 0.23 [95% CI, 0.09-0.62]; 2-6 hours: OR, 0.54 [95% CI, 0.39-0.73]; &gt;6 hours: OR, 0.70 [95% CI, 0.33-1.50];<i>P</i> = .12 for interaction). However, for the primary composite outcome, there was no benefit based on (1) total ischemic time (&lt;2 hours: hazard ratio [HR], 0.77 [95% CI, 0.46-1.28]; 2-6 hours: HR, 1.03 [95% CI, 0.85-1.25]; &gt;6 hours: HR, 0.87 [95% CI, 0.60-1.27];<i>P</i> = .46 for interaction) or (2) FMC-to-device time (&lt;60 minutes: HR, 1.14 [95% CI, 0.66-1.95]; 60-90 minutes: HR, 0.94 [95% CI, 0.67-1.32]; &gt;90-120 minutes: HR, 1.19 [95% CI, 0.85-1.67]; &gt;120 minutes: HR, 0.89 [95% CI, 0.70-1.14];<i>P</i> = .54 for interaction). In a multivariable analysis, both total ischemic time (&gt;2 hours: HR, 1.26 [95% CI, 1.00-1.58) and FMC-to-device time (&gt;120 minutes: HR, 1.45 [95% CI, 1.18-1.79]) were independently associated with CV mortality. <h3>Conclusions and Relevance</h3> This analysis suggests that thrombus aspiration does not appear to be associated with an improvement in clinical outcomes regardless of ischemic time. In the current STEMI era, both total ischemic time and FMC-to-device times continue to be important factors associated with mortality. <h3>Trial Registration</h3> ClinicalTrials.gov Identifier:NCT01149044